Abnormal T regulatory cells (Tregs: FOXP3+, CTLA-4+), myeloid-derived suppressor cells (MDSCs: monocytic, granulocytic) and polarised T helper cell profiles (Th1, Th2, Th17) in women with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC) and surgery: failure of abolition of abnormal treg profile with treatment and correlation of treg levels with pathological response to NAC

被引:46
作者
Verma, Chandan [1 ]
Eremin, Jennifer M. [2 ]
Robins, Adrian [3 ]
Bennett, Andrew J. [4 ]
Cowley, Gerard P. [5 ]
El-Sheemy, Mohamed A. [2 ,6 ]
Jibril, Jibril A. [2 ]
Eremin, Oleg [1 ,2 ]
机构
[1] Univ Nottingham, Queens Med Ctr, Div Gastrointestinal Surg, Nottingham NG7 2UH, England
[2] Lincoln Cty Hosp, Dept Res & Dev, Lincoln Breast Unit, Lincoln LN2 5QY, England
[3] Queens Med Ctr, Sch Mol Med Sci, Nottingham NG7 2UH, England
[4] Univ Nottingham, Sch Med, Queens Med Ctr, Sch Biomed Sci,FRAME Lab, Nottingham NG7 2UH, England
[5] Lincoln Cty Hosp, Dept Pathol, PathLinks, Lincoln LN2 5QY, England
[6] Lincoln Univ, Sch Life Sci, Lincoln LN6 7TS, England
关键词
Breast cancer; Tregs; Myeloid-derived suppressor cells; Cytokines; Chemotherapy and surgery; PERIPHERAL-BLOOD; TUMOR MICROENVIRONMENT; IMMUNE-RESPONSE; LYMPH-NODES; CYCLOPHOSPHAMIDE; EXPRESSION; CARCINOMA; IMMUNOTHERAPY; PROGRESSION; DOXORUBICIN;
D O I
10.1186/1479-5876-11-16
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Host defences play a key role in tumour growth. Some of the benefits of chemotherapy may occur through modulation of these defences. The aim of this study was to define the status of regulatory cells in women with large and locally advanced breast cancers (LLABCs) undergoing neoadjuvant chemotherapy (NAC) and surgery. Methods: Bloods were collected from patients (n = 56) before, during and following NAC, and surgery. Controls (n = 10) were healthy, age-matched females donors (HFDs). Blood mononuclear cells (BMCs) were isolated and T regulatory cells (Tregs) (n = 31) determined. Absolute numbers (AbNs) of Tregs and myeloid-derived suppressor cells (MDSCs) were ascertained from whole blood (n = 25). Reverse transcriptase polymerase chain reaction analysis determined Treg mRNA (n = 16). In vitro production of Th1, Th2 and Th17 cytokines (n = 30), was documented. Patients were classified as clinical responders by magnetic resonance mammography after two cycles of NAC and as pathological responders using established criteria, following surgery. Results: Patients with LLABCs had significantly increased circulating Tregs (>= 6 fold AbN and percentage (%)) and MDSCs (>= 1.5 fold AbN (p = 0.025)). Percentage of FOXP3(+) Tregs in blood predicted the response of the LLABCs to subsequent NAC (p = 0.04). Post NAC blood Tregs (%) were significantly reduced in patients where tumours showed a good pathological response to NAC (p = 0.05). Blood MDSCs (granulocytic, monocytic) were significantly reduced in all patients, irrespective of the pathological tumour response to chemotherapy. NAC followed by surgery failed to restore blood Tregs to normal levels. MDSCs, however, were reduced to or below normal levels by NAC alone. Invitro Th1 profile (IL-1 beta, IL-2, INF-gamma, TNF-alpha) was significantly reduced (p <= 0.009), whilst Th2 (IL-4, IL-5) was significantly enhanced (P <= 0.004). Th1 and Th2 (IL-5) were unaffected by NAC and surgery. IL-17A was significantly increased (p <= 0.023) but unaffected by chemotherapy and surgery. Conclusion: Women with LLABCs have abnormal blood regulatory cell levels (Tregs and MDSCs) and cytokine profiles (Th1, Th2, Th17). NAC followed by surgery failed to abolish the abnormal Treg and Th profiles. There was a significant correlation between the circulatory levels of Tregs and the pathological response of the breast cancers to NAC.
引用
收藏
页数:16
相关论文
共 58 条
[1]  
Aloysius M, 2011, ESSENTIAL IMMUNOLOGY, P236
[2]  
Aloysius M., 2011, ESSENTIAL IMMUNOLOGY, P379
[3]   A low number of tumor-infiltrating FOXP3-positive cells during primary systemic chemotherapy correlates with favorable anti-tumor response in patients with breast cancer [J].
Aruga, Tomoyuki ;
Suzuki, Eiji ;
Saji, Shigehira ;
Horiguchi, Shin-Ichirou ;
Horiguchi, Kazumi ;
Sekine, Susumu ;
Kitagawa, Dai ;
Funata, Nobuaki ;
Toi, Masakazu ;
Sugihara, Kenichi ;
Kuroi, Katsumasa .
ONCOLOGY REPORTS, 2009, 22 (02) :273-278
[4]   Increase of CD4+CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma:: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+CD25+ T lymphocytes [J].
Audia, S. ;
Nicolas, A. ;
Cathelin, D. ;
Larmonier, N. ;
Ferrand, C. ;
Foucher, P. ;
Fanton, A. ;
Bergoin, E. ;
Maynadie, M. ;
Arnould, L. ;
Bateman, A. ;
Lorcerie, B. ;
Solary, E. ;
Chauffert, B. ;
Bonnotte, B. .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2007, 150 (03) :523-530
[5]   Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse [J].
Bates, Gaynor J. ;
Fox, Stephen B. ;
Han, Cheng ;
Leek, Russell D. ;
Garcia, Jose F. ;
Harris, Adrian L. ;
Banham, Alison H. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (34) :5373-5380
[6]   Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy [J].
Baxevanis, Constantin N. ;
Perez, Sonia A. ;
Papamichail, Michael .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2009, 58 (03) :317-324
[7]   Transforming growth factor beta (TGF-β) and inflammation in cancer [J].
Bierie, Brian ;
Moses, Harold L. .
CYTOKINE & GROWTH FACTOR REVIEWS, 2010, 21 (01) :49-59
[8]   Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival [J].
Curiel, TJ ;
Coukos, G ;
Zou, LH ;
Alvarez, X ;
Cheng, P ;
Mottram, P ;
Evdemon-Hogan, M ;
Conejo-Garcia, JR ;
Zhang, L ;
Burow, M ;
Zhu, Y ;
Wei, S ;
Kryczek, I ;
Daniel, B ;
Gordon, A ;
Myers, L ;
Lackner, A ;
Disis, ML ;
Knutson, KL ;
Chen, LP ;
Zou, WP .
NATURE MEDICINE, 2004, 10 (09) :942-949
[9]   Paradoxical roles of the immune system during cancer development [J].
de Visser, KE ;
Eichten, A ;
Coussens, LM .
NATURE REVIEWS CANCER, 2006, 6 (01) :24-37
[10]   Inflammation and breast cancer - Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression [J].
DeNardo, David G. ;
Coussens, Lisa M. .
BREAST CANCER RESEARCH, 2007, 9 (04)